573 related articles for article (PubMed ID: 27159395)
1. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Mehnert JM; Panda A; Zhong H; Hirshfield K; Damare S; Lane K; Sokol L; Stein MN; Rodriguez-Rodriquez L; Kaufman HL; Ali S; Ross JS; Pavlick DC; Bhanot G; White EP; DiPaola RS; Lovell A; Cheng J; Ganesan S
J Clin Invest; 2016 Jun; 126(6):2334-40. PubMed ID: 27159395
[TBL] [Abstract][Full Text] [Related]
2. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
[TBL] [Abstract][Full Text] [Related]
3. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
Gong J; Wang C; Lee PP; Chu P; Fakih M
J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
[TBL] [Abstract][Full Text] [Related]
4. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
[TBL] [Abstract][Full Text] [Related]
6. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
7. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
8. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
van Gool IC; Eggink FA; Freeman-Mills L; Stelloo E; Marchi E; de Bruyn M; Palles C; Nout RA; de Kroon CD; Osse EM; Klenerman P; Creutzberg CL; Tomlinson IP; Smit VT; Nijman HW; Bosse T; Church DN
Clin Cancer Res; 2015 Jul; 21(14):3347-3355. PubMed ID: 25878334
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.
Veneris JT; Lee EK; Goebel EA; Nucci MR; Lindeman N; Horowitz NS; Lee L; Raut CP; Crotzer D; Matulonis U; Konstantinopoulos PA; Campos S
Gynecol Oncol; 2019 Jun; 153(3):471-478. PubMed ID: 30935717
[TBL] [Abstract][Full Text] [Related]
10. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Bellone S; Bignotti E; Lonardi S; Ferrari F; Centritto F; Masserdotti A; Pettinella F; Black J; Menderes G; Altwerger G; Hui P; Lopez S; de Haydu C; Bonazzoli E; Predolini F; Zammataro L; Cocco E; Ferrari F; Ravaggi A; Romani C; Facchetti F; Sartori E; Odicino FE; Silasi DA; Litkouhi B; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Jan; 144(1):146-152. PubMed ID: 27894751
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ
Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754
[TBL] [Abstract][Full Text] [Related]
12. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response.
Li HD; Lu C; Zhang H; Hu Q; Zhang J; Cuevas IC; Sahoo SS; Aguilar M; Maurais EG; Zhang S; Wang X; Akbay EA; Li GM; Li B; Koduru P; Ly P; Fu YX; Castrillon DH
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32699191
[TBL] [Abstract][Full Text] [Related]
13. POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing.
Konstantinopoulos PA; Matulonis UA
Cancer; 2015 Feb; 121(3):331-4. PubMed ID: 25224324
[No Abstract] [Full Text] [Related]
14. Endometrial cancer with a POLE mutation progresses frequently through the type I pathway despite its high-grade endometrioid morphology: a cohort study at a single institution in Japan.
Monsur M; Yamaguchi M; Tashiro H; Yoshinobu K; Saito F; Erdenebaatar C; Li C; Iwagoi Y; Ohba T; Iyama KI; Katabuchi H
Med Mol Morphol; 2021 Jun; 54(2):133-145. PubMed ID: 33399963
[TBL] [Abstract][Full Text] [Related]
15. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction.
Li Y; Bian Y; Wang K; Wan XP
BMC Med Genet; 2019 Dec; 20(1):202. PubMed ID: 31864301
[TBL] [Abstract][Full Text] [Related]
16. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
17. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?
Snyder A; Wolchok JD
Cancer Discov; 2016 Nov; 6(11):1210-1211. PubMed ID: 27807100
[TBL] [Abstract][Full Text] [Related]
19. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.
Bellone S; Centritto F; Black J; Schwab C; English D; Cocco E; Lopez S; Bonazzoli E; Predolini F; Ferrari F; Silasi DA; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2015 Jul; 138(1):11-7. PubMed ID: 25931171
[TBL] [Abstract][Full Text] [Related]
20. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
